Xyrem REMS Grudgingly Approved; FDA Worries About Blocked Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Single-pharmacy distribution system for Jazz’s narcolepsy treatment isn’t necessarily needed, FDA says, even as it clears that risk management plan.